Benefits
Long-term bone density support
In healthy postmenopausal women, MenaQ7® (180 mcg/day) reduced the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck vs placebo. Effects are modest compared with pharmaceutical osteoporosis therapy but reached statistical significance over the multi-year window.
Arterial stiffness and vascular elasticity
Long-term MenaQ7® supplementation was associated with improvements in carotid-femoral pulse wave velocity and stiffness index in healthy postmenopausal women, alongside reductions in inactive (uncarboxylated) matrix Gla protein, supporting the proposed vascular role of MK-7 in keeping MGP active.
Activation of vitamin-K-dependent Gla proteins
MenaQ7® reliably reduces circulating inactive osteocalcin and matrix Gla protein, indicating improved carboxylation status of these bone- and vascular-protective proteins — a mechanistic biomarker that underpins MK-7's clinical positioning.
Long half-life and once-daily dosing
MK-7 has a plasma half-life of roughly 3 days versus about 1 hour for MK-4. Once-daily MenaQ7® dosing can therefore maintain stable, biologically meaningful circulating levels — practical for both consumer and clinical formulations.
Original commercial all-trans MK-7
MenaQ7® was the first commercially established all-trans MK-7 ingredient and has supported the clinical trial base that underpins most other branded MK-7 products. It remains a benchmark reference for clinical evidence in the MK-7 category.
Mechanism of action
Gamma-carboxylation of Gla-domain proteins
MK-7 is an essential cofactor for gamma-glutamyl carboxylase, which converts glutamate residues in Gla-domain proteins (osteocalcin, matrix Gla protein, GAS6, Protein S) to gamma-carboxyglutamate, enabling these proteins to bind calcium and perform their physiological functions.
Osteocalcin activation and bone matrix formation
Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and helps incorporate calcium into the bone matrix. Inadequate K2 leaves osteocalcin undercarboxylated and impairs this binding, contributing to age-related bone loss that MK-7 supplementation may help mitigate.
Matrix Gla protein activation and vascular protection
Carboxylated matrix Gla protein is the body's primary inhibitor of vascular calcification, binding calcium ions in vessel walls and limiting calcium phosphate deposition. K2 deficiency leaves MGP inactive and is associated with greater arterial calcification, which MK-7 supplementation may help reduce.
Long-chain menaquinone tissue distribution
Compared with shorter menaquinones, MK-7's longer isoprenoid side chain supports efficient incorporation into circulating lipoproteins and extra-hepatic tissue delivery — explaining its disproportionate effect on extra-hepatic Gla proteins like osteocalcin and MGP relative to MK-4.
Clinical trials
Randomized, double-blind, placebo-controlled trial of MenaQ7® MK-7 (180 mcg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: bone mineral density at lumbar spine and femoral neck, osteocalcin carboxylation status. Published in Osteoporosis International.
244 healthy postmenopausal women; 3-year intervention.
MenaQ7® MK-7 significantly improved osteocalcin carboxylation and reduced age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck vs placebo. Effects were modest in magnitude compared with pharmaceutical osteoporosis therapy but reached statistical significance over the 3-year window.
Randomized, double-blind, placebo-controlled trial of MenaQ7® MK-7 (180 mcg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: carotid–femoral pulse wave velocity, stiffness index, circulating inactive matrix Gla protein. Published in Thrombosis and Haemostasis.
244 healthy postmenopausal women; 3-year intervention.
Three-year MenaQ7® supplementation was associated with improvements in carotid–femoral pulse wave velocity and stiffness index vs placebo, alongside significant reductions in inactive matrix Gla protein, supporting MK-7's vascular health rationale.
Pharmacokinetic study comparing synthetic vitamin K1 (phylloquinone) and natto-derived MK-7 supplementation in healthy adults to characterize plasma kinetics, half-life, and accumulation. Published in Blood.
Healthy adult volunteers; pharmacokinetic study.
MK-7 demonstrated a very long plasma half-life and far more stable serum levels than phylloquinone, with 7- to 8-fold accumulation during prolonged intake. This pharmacokinetic profile supports once-daily dosing of MenaQ7® and explains its disproportionate effect on extra-hepatic vitamin K–dependent proteins.